JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Metabolism-associated marker gene-based predictive model for prognosis, targeted therapy, and immune landscape in ovarian cancer: an integrative analysis of single-cell and bulk RNA sequencing with spatial transcriptomics

  • 0Department of Acupuncture, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200086, China.
Bmc Women's Health +

|

May 17, 2025

|

May 17, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A novel prognostic model for ovarian cancer (OC) was developed using metabolism-related genes (MRGs). This model identifies potential therapeutic targets and drugs, including candesartan and PD-123319, for improved OC treatment strategies.

Area Of Science

  • Oncology
  • Metabolomics
  • Genomics

Background

  • Ovarian cancer (OC) has a high mortality rate, often due to metastasis, with limited effective biomarkers and treatments.
  • Metabolic pathways like glycolysis, lipid, choline, and sphingolipid metabolism are crucial in OC development and progression.

Purpose Of The Study

  • To identify potent prognostic biomarkers for OC.
  • To explore novel therapeutic drugs and targets for advancing OC treatment.

Main Methods

  • Single-cell RNA sequencing (scRNA-seq) and bulk RNAseq data were analyzed to identify metabolism-related genes (MRGs).
  • A prognostic model was constructed using 12 MRGs and validated through pan-cancer analysis, immune microenvironment assessment, and mutation profiling.
  • Drug prediction was performed using the CMap database, and the efficacy of targeting TREM1 was validated experimentally.

Main Results

  • A prognostic model comprising 12 MRGs was developed, identifying C1QC+ TAMs and FCN1+ RTMs as key monocyte subpopulations in OC.
  • The model revealed significant metabolic and genomic variations across tumors and predicted that low-risk patients have higher anti-cancer immunity.
  • Candesartan and PD-123319 were identified as potential drugs targeting ATGR2, and TREM1 downregulation inhibited OC cell proliferation and migration.

Conclusions

  • The developed MRG-based prognostic model shows potential as an effective biomarker for ovarian cancer.
  • Candesartan and PD-123319 represent promising therapeutic agents for OC, potentially through targeting ATGR2.

Keywords: